Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel function after surgery.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Clients benefit from reliable delivery schedules and responsive technical support.

Mestinon acts as an acetylcholinesterase inhibitor, improving neuromuscular transmission in disorders of the cholinergic system. - Myasthenia gravis: enhances muscle strength by increasing acetylcholine at the neuromuscular junction. - Postoperative ileus: stimulates intestinal motility to facilitate recovery of bowel function after abdominal surgery. - Myasthenic crisis (acute exacerbation): provides rapid symptomatic relief by augmenting cholinergic transmission.

Pyridostigmine bromide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Increased salivation - Muscle cramps

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bradycardia - Anaphylactic reaction

When prescribing pyridostigmine bromide, several precautions should be observed to minimize risk. - Renal impairment: adjust dose because the drug is primarily excreted unchanged by the kidneys. - Asthma or COPD: monitor for bronchospasm due to increased cholinergic activity. - Concomitant anticholinergic drugs: may reduce therapeutic effect. - Signs of cholinergic excess: watch for muscle twitching, sweating, or diarrhea and adjust dose accordingly. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pyridostigmine bromide can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other cholinesterase inhibitors (e.g., neostigmine): additive cholinergic effects may precipitate crisis. - Anticholinergic agents (e.g., atropine, antihistamines): antagonize therapeutic action.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade. - Magnesium supplements: can enhance neuromuscular transmission inhibition. - Beta‑blockers: may exacerbate bradycardia. - Potassium‑sparing diuretics: increase risk of hyperkalemia in renal impairment.